返回
Inter-tissue communication in cancer cachexia
DOI:10.1038/s41574-018-0123-0.png)
摘要
En 中文
Cachexia is a systemic condition that occurs during many neoplastic diseases, such as cancer. Cachexia in cancer is characterized by loss of body weight and muscle and by adipose tissue wasting and systemic inflammation. Cancer cachexia is often associated with anorexia and increased energy expenditure. Even though the cachectic condition severely affects skeletal muscle, a tissue that accounts for similar to 40% of total body weight, it represents a multi-organ syndrome that involves tissues and organs such as white adipose tissue, brown adipose tissue, bone, brain, liver, gut and heart. Indeed, evidence suggests that non-muscle tissues and organs, as well as tumour tissues, secrete soluble factors that act on skeletal muscle to promote wasting. In addition, muscle tissue also releases various factors that can interact with the metabolism of other tissues during cancer. In this Review, we examine the effect of non-muscle tissues and inter-tissue communication in cancer cachexia and discuss studies aimed at developing novel therapeutic strategies for the condition.
Keyword:
SUBCUTANEOUS ADIPOSE-TISSUE
GUT BARRIER DYSFUNCTION
ACUTE-PHASE PROTEINS
SKELETAL-MUSCLE
NATRIURETIC-PEPTIDE
WEIGHT-LOSS
ENERGY-EXPENDITURE
BROWN-FAT
HYPOTHALAMIC INFLAMMATION
INSULIN-RESISTANCE
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
40
论文数:
1.0W
被引数:
10.5W
机构
引用论文
Reduction of Smad2 caused by oxidative stress leads to necrotic death of hypertrophic chondrocytes associated with an endemic osteoarthritis
Rheumatology
IF0
Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research
DIABETES CARE
IF16.6
Browning of White Adipose Cells by Intermediate Metabolites: An Adaptive Mechanism to Alleviate Redox Pressure
DIABETES
IF7.5
Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues - Association with cytokine expression, insulin resistance, and reduction by pioglitazone
DIABETES
IF7.5

